{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/","result":{"pageContext":{"chapter":{"id":"67092bd7-2ab4-5e8b-8ead-5301454da4a8","slug":"acetylcholinesterase-inhibitors","fullItemName":"Acetylcholinesterase inhibitors","depth":2,"htmlHeader":"<!-- begin field 52f82f1f-1cfe-4c58-9a1b-223b7f20c4f5 --><h2>Acetylcholinesterase inhibitors</h2><!-- end field 52f82f1f-1cfe-4c58-9a1b-223b7f20c4f5 -->","summary":"","htmlStringContent":"<!-- begin item b00f3f39-1438-4914-8aa6-5950c045740f --><!-- begin field ddf8c447-2ed2-4e6f-9d2c-4e4304cf84d4 --><ul><li><strong>When considering acetylcholinesterase (AChE) inhibitors (donepezil, galantamine and rivastigmine) </strong>prescribers should only start treatment with these on the advice of a clinician who has the necessary knowledge and skills.<ul><li>Once a decision has been made to start an AChE inhibitor, the first prescription may be made in primary care.</li><li>Treatment may be continued in primary care under a shared care protocol.</li><li>Ensure that local arrangements for prescribing, supply and treatment review follow the NICE guideline on medicines optimisation.</li><li>Do not stop AChE inhibitors in people with Alzheimer's disease because of disease severity alone.</li></ul></li><li>For further information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/dementia/management/follow-up-of-confirmed-dementia-in-primary-care/#specialist-treatment\">Specialist dementia treatment</a>.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2018b</a>] </p><!-- end field ddf8c447-2ed2-4e6f-9d2c-4e4304cf84d4 --><!-- end item b00f3f39-1438-4914-8aa6-5950c045740f -->","topic":{"id":"de9cbb4d-2d69-500f-be27-dc83f76dc3ba","topicId":"2491e3e7-cc21-42b9-8972-e54804b4782f","topicName":"Dementia","slug":"dementia","lastRevised":"Last revised in October 2020","chapters":[{"id":"af834011-0042-530a-8f9a-acd5828e0a34","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a0360b83-4555-5079-897f-12b2d555c1af","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"52cd8e36-39cd-5259-8819-bd96087b0265","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"60bd6b27-027f-56a6-a018-a1d694a6a2f3","slug":"changes","fullItemName":"Changes"},{"id":"7ced1224-30c2-5f30-9caf-3764f3665ae4","slug":"update","fullItemName":"Update"}]},{"id":"fae05cff-ad98-52fa-89b4-b97369195d59","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2f3b4bd3-e7cf-5492-afe0-0a5b230eab7e","slug":"goals","fullItemName":"Goals"},{"id":"9104785e-e491-5ca3-b3d3-7e951385bce9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a9c56eb4-bc0e-51cc-b486-a54c23906bc0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ebf62eba-a4cd-536c-8c9f-c9505b0e7482","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a71b8dc2-79f8-5d24-b668-c792abc5a624","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c87232ba-6926-5ff2-98d2-f8839b0c0d37","slug":"nice-quality-standards","fullItemName":"NICE Quality Standards"}]},{"id":"825c29c3-9d55-54ae-b54d-8ee2ac796e97","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"46c6316f-eec0-580a-80ec-2112d2f0122f","slug":"definition","fullItemName":"Definition"},{"id":"f485482d-0d4e-52cb-9df4-3548bc72a566","slug":"causes","fullItemName":"Causes"},{"id":"87101d89-6073-57cc-b247-48be586ef185","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"58f6ec5a-c90b-5e64-a476-fc9fca39c6ae","slug":"prevalence","fullItemName":"Prevalence"},{"id":"994469e3-f824-5f48-b755-7f74dd360680","slug":"prognosis","fullItemName":"Prognosis"},{"id":"718f9ed4-d725-5f6e-a86f-5df88719cd52","slug":"complications","fullItemName":"Complications"}]},{"id":"366bcbe3-827a-5e08-9d81-8de84e46fefd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"565bac2a-ada3-5b0a-ab7d-6681501b2c4a","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"4c0fe55f-40c9-5a1c-8cf3-1ec8d88406d5","slug":"assessment","fullItemName":"Assessment"},{"id":"ef7780bd-8e94-5f95-870f-92ab930c4365","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3069f5e5-519f-50ec-81b7-c8948a5b3117","fullItemName":"Management","slug":"management","subChapters":[{"id":"c6c0cbc2-18fc-5bf8-973d-bc38b9001f28","slug":"suspected-dementia","fullItemName":"Scenario: Suspected dementia"},{"id":"6320a2da-e9d6-5f57-94d9-0433261edf89","slug":"follow-up-of-confirmed-dementia-in-primary-care","fullItemName":"Scenario: Follow up of confirmed dementia in primary care"},{"id":"343a59fa-439e-5ab9-9d3b-28a893d55d2f","slug":"management-of-end-stage-dementia","fullItemName":"Scenario: Management of end-stage dementia"}]},{"id":"9a2639de-07aa-5fe3-8f09-5c005f9c29dd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"58ed8441-e3ca-566e-9afb-92a5ba60b1dd","slug":"haloperidol","fullItemName":"Haloperidol"},{"id":"67092bd7-2ab4-5e8b-8ead-5301454da4a8","slug":"acetylcholinesterase-inhibitors","fullItemName":"Acetylcholinesterase inhibitors"},{"id":"f4ced652-a6de-5e19-ae37-6de43dfd8104","slug":"lorazepam","fullItemName":"Lorazepam"},{"id":"45d5f01b-c1c2-53dc-91b4-8f7a90983fd5","slug":"memantine-hydrochloride","fullItemName":"Memantine hydrochloride"}]},{"id":"1e87c908-2ab5-5cba-8d6a-958c03f7a6cd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fc7a2bcf-854b-5ca4-9b02-2dcaaebe1162","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7bcb26a3-cc69-5201-9fd9-6353e27b412f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c383917-58d0-5036-8217-5d9fd81cb2cb","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fdb8af52-aeee-52bd-be79-c5534939d42f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a9f930f3-f8b6-5c8f-b8ca-b3155e0c23d3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"668c11fa-1873-58d4-b0e2-3eab90e8fbff","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67c4aef9-fbf4-5bf6-8dc5-c501f74b1fe3","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"9a2639de-07aa-5fe3-8f09-5c005f9c29dd","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d12ba349-33d8-5192-9b2d-df9252135eb5","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field c8ad2c07-c7eb-4ff6-99dd-8075e6a3b1f0 --><h3>What dose of acetylcholinesterase inhibitors is usually prescribed?</h3><!-- end field c8ad2c07-c7eb-4ff6-99dd-8075e6a3b1f0 -->","summary":"","htmlStringContent":"<!-- begin item 0211b320-7195-4a33-9953-65e12f8dea5a --><!-- begin field b02765aa-b4d1-4a51-8c72-160a9baad1ec --><p><strong>Acetylcholinesterase (AChE) inhibitors should <em>always</em> be initiated and supervised by specialists experienced in the management of dementia. However, treatment may be continued in primary care under a shared-care protocol. Specialist advice should be sought if a change in dose is required or if the treatment needs to be stopped</strong><strong>. </strong><strong>As a general guide, the usual doses are </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">NICE, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<strong>:</strong></p><ul><li><strong>Donepezil</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<ul><li>For most people, initially 5 mg orally once daily at bedtime, increased if tolerated and necessary after one month to a maximum of 10 mg daily.</li></ul></li><li><strong>Galantamine </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<ul><li>For most people, initially 4 mg orally twice daily for 4 weeks, increased to 8 mg twice daily for at least 4 weeks; maintenance dose is 8–12 mg twice daily. Prolonged release preparations are available.</li><li>For people with moderate hepatic impairment: <ul><li>Immediate-release preparations — initially 4 mg once daily (preferably in the morning) for at least 7 days, then 4 mg twice daily for at least 4 weeks; maximum dose is 8 mg twice daily.</li></ul></li><li>Galantamine is contraindicated in people with severe renal impairment, and no dose adjustment is required for people with mid renal impairment</li><li>Warn people taking galantamine and their family/carers of the signs of serious skin reactions (including Stevens-Johnson syndrome, erythema multiforme, and acute generalised exanthematous pustulosis). <ul><li>Advise them to stop taking galantamine immediately and seek medical advice if symptoms occur.</li></ul></li><li>Monitor weight during therapy.</li></ul></li><li><strong>Rivastigmine</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<ul><li>Orally — initially 1.5 mg twice daily, increased in steps of 1.5 mg twice daily at intervals of at least 2 weeks, according to response and tolerance. The usual range is 3–6 mg twice daily, and the maximum dose is 6 mg twice daily. If treatment is interrupted for more than several days, oral rivastigmine should be re-titrated from 1.5 mg twice daily.</li><li>Transdermal application — there is a risk of fatal overdose with patch administration errors. The person and thier family/carers should be clearly informed of the patch administration instructions, in particular to remove the previous day's patch before applying a new patch.<ul><li>Initially the 4.6 mg/24 hours patch should be applied to clean, dry, non-hairy, non-irritated skin on the back, upper arm, or chest. This should be removed after 24 hours and a replacement patch applied on a different area (the person should avoid using the same area for 14 days). </li><li>After at least 4 weeks, if well tolerated, the dose should be increased to the usual maintenance dose of 9.5 mg/24 hours patch daily.</li><li>After a further 6 months, if well tolerated and cognitive deterioration or functional decline are demonstrated, the dose can be increased to 13.3 mg/24 hours patch daily (this should be done with caution in people who weigh less than 50 kg). </li><li>If treatment is interrupted for more than three days, transdermal rivastigmine should be re-titrated from a 4.6 mg/24 hours patch.</li></ul></li><li>The manufacturer advises that treatment with rivastigmine should be temporarily stopped if gastro-intestinal adverse effects occur, and withheld until their resolution — the dose should be re-titrated if treatment is interrupted for more than 3 days.</li></ul></li></ul><!-- end field b02765aa-b4d1-4a51-8c72-160a9baad1ec --><!-- end item 0211b320-7195-4a33-9953-65e12f8dea5a -->","subChapters":[]},{"id":"f52e8d5d-17e4-5ca8-80fa-7824e8d8b0b2","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 51816ff7-1814-4c60-9ab8-cc8fa1788ac7 --><h3>What are the adverse effects of acetylcholinesterase inhibitors?</h3><!-- end field 51816ff7-1814-4c60-9ab8-cc8fa1788ac7 -->","summary":"","htmlStringContent":"<!-- begin item cf189867-550d-41e5-89fb-cabd64cc5a51 --><!-- begin field 9e53b148-d672-4fd3-8d64-d5a1c845cf85 --><p><strong>Acetylcholinesterase (AChE) inhibitors should <em>always</em> be initiated and supervised by specialists experienced in the management of dementia. However, treatment may be continued in primary care under a shared-care protocol. Specialist advice should be sought if a change in dose is required, or if the treatment needs to be stopped.</strong></p><ul><li><strong>Adverse effects of donepezil include</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<strong>:</strong><ul><li>Commonly, nausea, vomiting, anorexia, diarrhoea, fatigue, insomnia, headache, dizziness, syncope, abnormal dreams, hallucinations, agitation, aggression, muscle cramps, urinary incontinence, rash, and pruritus.</li><li>Rarely, extrapyramidal symptoms, sinoatrio block, atrioventricular (AV) block, liver dysfunction (including hepatitis), and neuroleptic malignant syndrome (NMS).<ul><li>NMS is a potentially life-threatening condition characterized by hyperthermia, muscle rigidity, autonomic instability, and fluctuating consciousness). Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure.</li><li>The risk of NMS is increased in people receiving concomitant antipsychotics.</li><li>If a person develops signs and symptoms of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, donepezil treatment should be discontinued.</li></ul></li></ul></li><li><strong>Adverse effects of galantamine include</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<strong>:</strong><ul><li>Commonly, vomiting, nausea, abdominal pain, diarrhoea, dyspepsia, decreased appetite, weight loss (monitor the person's weight during treatment with galantamine), bradycardia, hypertension, syncope, hallucinations, depression, dizziness, tremor, headache, fatigue, malaise, and muscle spasm.</li><li>Less commonly, retching, dehydration, hypotension, flushing, palpitation, arrhythmias, first-degree AV block, taste disturbance, paraesthesia, seizures, hypersomnia, muscular weakness, blurred vision, tinnitus, and sweating.</li><li>Rarely, exacerbation of Parkinson’s disease, hepatitis, and serious skin reactions.<ul><li>Warn people taking galantamine and their family/carers of the signs of serious skin reactions (including Stevens-Johnson syndrome, erythema multiforme, and acute generalised exanthematous pustulosis).</li><li>Galantamine should be discontinued at the first appearance of a skin rash.</li></ul></li></ul></li><li><strong>Adverse effects of rivastigmine include</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<strong>:</strong><ul><li>Commonly, nausea, vomiting, diarrhoea, dyspepsia, anorexia, weight loss, increased salivation, abdominal pain, bradycardia, dizziness, headache, drowsiness, malaise, agitation, anxiety, tremor, confusion, insomnia, extrapyramidal symptoms (and worsening of Parkinson’s disease), urinary incontinence, and sweating.<ul><li>The manufacturer advises that treatment with transdermal rivastigmine should be temporarily stopped if gastrointestinal adverse effects occur [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016c</a>].</li></ul></li><li>Less commonly, atrial fibrillation, AV block, depression, and syncope.</li><li>Rarely, gastric and duodenal ulceration, pancreatitis, tachycardia, hypertension, angina, seizures, hallucinations and rash.</li><li>Dehydration, hepatitis, restlessness, aggression, sick sinus syndrome, and skin hypersensitivity (unknown frequency).</li></ul></li><li><strong>Ability to drive</strong> — AChE inhibitors can cause fatigue, dizziness, and muscle cramps, mainly when initiating or increasing the dose. Routinely assess the person's ability to drive [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>].</li></ul><!-- end field 9e53b148-d672-4fd3-8d64-d5a1c845cf85 --><!-- end item cf189867-550d-41e5-89fb-cabd64cc5a51 -->","subChapters":[]},{"id":"436e6ac1-84de-5165-9398-748247546b09","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 3ee2b47f-c6d3-47be-82bc-790851915b66 --><h3>What are the contraindications and cautions with acetylcholinesterase inhibitors?</h3><!-- end field 3ee2b47f-c6d3-47be-82bc-790851915b66 -->","summary":"","htmlStringContent":"<!-- begin item 426f4e9b-aaeb-4f42-8c98-0d009ee3c265 --><!-- begin field 772a39c6-5ae4-40c0-9d9c-0f64a33c8983 --><ul><li><strong>Acetylcholinesterase (AChE) inhibitors should <em>always</em> be initiated and supervised by specialists experienced in the management of dementia. However, treatment may be continued in primary care under a shared-care protocol.</strong></li><li><strong>Contraindications:</strong><ul><li><strong>Donepezil hydrochloride </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<ul><li>Known hypersensitivity to donepezil hydrochloride, piperidine derivatives, or any excipients used in the formulation. </li><li>Pregnancy and breastfeeding.</li></ul></li><li><strong>Galantamine </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<ul><li>Hypersensitivity to galantamine or to any of the excipients.</li><li>Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 9 mL/minute/1.73 m2).</li><li>Severe hepatic impairment (Child-Pugh score greater than 9).</li><li>People who have both significant renal and hepatic dysfunction.</li><li>Urinary outflow obstruction.</li><li>Gastrointestinal obstruction.</li><li>During recovery from bladder or gastrointestinal surgery.</li><li>Pregnancy and breast feeding</li></ul></li><li><strong>Rivastigmine</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<ul><li>Known hypersensitivity to rivastigmine, other carbamate derivatives, or to any of the excipients used in the formulation.</li><li>Previous history of application site reactions suggestive of allergic contact dermatitis with the rivastigmine patch.</li><li>Pregnancy and breastfeeding.</li></ul></li></ul></li><li><strong>Cautions</strong><ul><li><strong>Donepezil hydrochloride</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<ul><li>Sick sinus syndrome or other supraventricular conduction abnormalities.</li><li>Susceptibility to peptic ulcers including concurrent nonsteroidal anti-inflammatory (NSAID) use.</li><li>Asthma and chronic obstructive pulmonary disease (COPD).</li><li>Concomitant antipsychotic treatment — increased risk of neuroleptic malignant syndrome.</li></ul></li><li><strong>Galantamine</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<ul><li>Renal and hepatic impairment.</li><li>Cardiac disease (including sick sinus syndrome or other supraventricular conduction abnormalities, post myocardial infarction, unstable angina, new onset atrial fibrillation, second degree heart block or greater, and congestive heart failure) or in those who use medicinal products that significantly reduce heart rate concomitantly, such as digoxin and beta blockers.</li><li>Electrolyte disturbances (such as hyperkalaemia or hypokalaemia).</li><li>Susceptibility to peptic ulcers including concomitant use of NSAIDs.</li><li>History of severe asthma, COPD, or pulmonary infection.</li><li>History of seizures.</li></ul></li><li><strong>Rivastigmine</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<ul><li>Hepatic impairment.</li><li>Renal impairment.</li><li>Gastric or duodenal ulcers (or susceptibility to ulcers).</li><li>Sick sinus syndrome, or conduction abnormalities.</li><li>History of asthma or COPD.</li><li>History of seizures.</li><li>Bladder outflow obstruction.</li></ul></li></ul></li></ul><!-- end field 772a39c6-5ae4-40c0-9d9c-0f64a33c8983 --><!-- end item 426f4e9b-aaeb-4f42-8c98-0d009ee3c265 -->","subChapters":[]},{"id":"3d7194c0-bb78-572c-a7cc-252d7eff48f4","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 84545512-ffe8-4e3b-9f2a-0d8877625e1b --><h3>What drug interactions can occur with acetylcholinesterase inhibitors?</h3><!-- end field 84545512-ffe8-4e3b-9f2a-0d8877625e1b -->","summary":"","htmlStringContent":"<!-- begin item 97ac7a65-c278-44db-9864-3c12cf390689 --><!-- begin field 2e55e99c-5294-4cf6-a755-75ffc0c4890f --><p><strong>Acetylcholinesterase (AChE) inhibitors should <em>always</em> be initiated and supervised by specialists experienced in the management of dementia. However, treatment may be continued in primary care under a shared-care protocol. Specialist advice should be sought if a change in dose is required, the treatment needs to be stopped or an interacting drug is to be prescribed.</strong></p><ul><li><strong>Antimuscarinic drugs antagonize the effects of donepezil, galantamine and rivastigmine</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<strong>.</strong><ul><li>Many drugs have antimuscarinic effects:<ul><li>Concomitant use of two or more such drugs can increase adverse effects such as dry mouth, urine retention, and constipation. </li><li>Concomitant use can also lead to confusion in the elderly.</li></ul></li></ul></li><li><strong>Concurrent antipsychotic treatment increases the risk of neuroleptic malignant syndrome (NMS) </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<strong>. </strong><ul><li>If a person develops <a class=\"topic-reference internal-reference\" href=\"/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/#adverse-effects\">signs and symptoms</a> of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, treatment should be discontinued.</li></ul></li><li><strong>Other possible drug interactions include</strong><strong>:</strong><ul><li><strong>For donepezil</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<strong>:</strong><ul><li>Liver enzyme inhibitors — cytochrome P450 enzyme CYP3A4 inhibitors (such as ketoconazole and possibly itraconazole and erythromycin) and CYP2D6 inhibitors (such as quinidine and possibly fluoxetine) inhibit donepezil metabolism.</li><li>Liver enzyme inducers — enzyme inducers such as rifampicin, phenytoin, carbamazepine, and alcohol) may reduce plasma levels of donepezil.</li></ul></li><li><strong>For galantamine</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">ABPI, 2016b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dementia/references/\">BNF 71, 2016</a>]<strong>:</strong><ul><li>Liver enzyme inhibitors — CYP3A4 inhibitors (such as ketoconazole and erythromycin) and CYP2D6 inhibitors (such as paroxetine and fluoxetine) may increase the plasma concentration of galantamine.</li><li>Drugs that reduce the heart rate — galantamine may interact with drugs that significantly reduce the heart rate such as digoxin, beta blockers, certain calcium-channel blockers, and amiodarone.</li></ul></li></ul></li></ul><!-- end field 2e55e99c-5294-4cf6-a755-75ffc0c4890f --><!-- end item 97ac7a65-c278-44db-9864-3c12cf390689 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}